



#7
1103326-0072

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Lindberg et al.
Serial No. : 09/419,456
Filed : October 12, 1999
For : NEW COMPOUNDS
Examiner :
Group Art Unit :

I hereby certify that this paper is being
deposited with the United States Postal Service
as first class mail in an envelope addressed to:
Assistant Commissioner for Patents
Washington, D.C. 20231.

John M. Genova 32,224
Attorney Name PTO Reg. No.

John M Genova 11/12/99
Signature Date of Signature

11/23/1999 TSUGGS 00000001 231703 09419456
Sale Ref: 00000001 DAH: 231703 09419456
01 FC:148 110.00 CH

Assistant Commissioner for Patents
Washington, D.C. 20231

TERMINAL DISCLAIMER

Sir:

Astra Aktiebolag, a corporation created and existing under the laws of Sweden,
and having a business address at S-151 85 Södertälje, Sweden, hereby through its undersigned
agent, who is empowered to act on behalf of Astra Aktiebolag, represents that Astra Aktiebolag is
the owner of the entire right, title and interest of the above-identified patent application Serial No.

09/419,456 and of U.S. Patent No. 5,714,504 by Assignment recorded on April 17, 1995, Reel 7438, Frame 0120.

Astra Aktiebolag, by its undersigned agent, states that all evidentiary documents have been reviewed and certifies that, to the best of its knowledge and belief, title to Application Serial No. 09/419,456 and U.S. Patent No. 5,714,504 is in Astra Aktiebolag. The inventions claimed in U.S. Serial No. 09/419,456 and U.S. Patent No. 5,714,504 were commonly owned by Astra Aktiebolag at the time the later invention was made.

Astra Aktiebolag hereby disclaims, except as provided below, the terminal portion of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term as defined in 35 U.S.C. §§154 to 156 and 173 of prior U.S. Patent No. 5,714,504. Astra Aktiebolag hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period it and U.S. Patent No. 5,714,504 are commonly owned. This agreement runs with any patent granted on the above-identified application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§154 to 156 and 173 of U.S. Patent No. 5,714,504, in the event that the prior patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims canceled by a reexamination certificate, is reissued or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

In connection with the filing of this Terminal Disclaimer, the Commissioner is hereby authorized to charge the fee of \$110.00 as required by 37 C.F.R. § 1.20(d) to Deposit Account No. 23-1703.

Dated: November 12, 1999

Astra Aktiebolag



John M. Genova
Reg. No. 32,224
Attorney for Applicants

White & Case LLP
Patent Department
1155 Avenue of the Americas
New York, NY 10036-2787
(212) 819-8200